NCT02436707 - Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Biotech Hunter

Enrollment

129

Participants

Timeline

Start Date

October 27, 2015

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Lymphoma

Interventions

DRUG

Ibrutinib

DRUG

Rituximab

DRUG

Gemcitabine

DRUG

Dexamethasone

DRUG

Cisplatin

DRUG

Mesna

DRUG

Cyclophosphamide

DRUG

Etoposide

DRUG

G-CSF

DRUG

Selinexor

Trial Locations (12)

T2N 5G2

Arthur J.E. Child Comprehensive Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

BCCA - Vancouver, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

B3H 1V7

QEII Health Sciences Centre, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 2V7

Kingston Health Sciences Centre, Kingston

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

University Health Network, Toronto

H2X 3E4

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

G1J 1Z4

CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Québec

S4T 7T1

Allan Blair Cancer Centre, Regina